Anti-VEGF Therapy or Vitrectomy Surgery for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy.

The authors reflect on a study which assessed the effectiveness of the anti-vascular endothelial growth factor (anti-VEGF) agent aflibercept versus vitrectomy with panretinal photocoagulation in treating patients with proliferative diabetic retinopathy with vitreous hemorrhage. Based on the results, it is recommended that patients should have access to early rescue vitrectomy surgery if aflibercept is used as initial treatment. Diabetic retinopathy is the leading cause of blindness.